Catalent Completes $4.7 Billion Debt Refinancing to Strengthen Financial Position and Support Long-Term Growth
Catalent, Inc., a global contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotechnology and healthcare industries, has successfully completed a major debt refinancing transaction designed to strengthen its financial position, reduce borrowing costs and provide greater flexibility to support future investments. The refinancing represents an important step in the company’s ongoing efforts to build a stronger and more financially resilient business while continuing to expand the capabilities and services it provides to customers.
The transaction includes a new $4.1 billion equivalent seven-year Term Loan B facility and a $600 million revolving credit facility. Together, the new financing arrangements replace Catalent’s existing Term Loan B and are expected to materially improve the company’s cost of capital. Based on the terms of the refinancing, Catalent expects to reduce its annual interest expense by approximately $100 million, providing additional financial capacity that can be directed toward business priorities, operational investments and customer-focused initiatives.
The refinancing comes at a significant time for Catalent as the company continues to focus on strengthening its operations and supporting customers across the pharmaceutical and biotechnology sectors. As a major CDMO, Catalent plays a critical role in helping customers develop, manufacture and deliver medicines and other healthcare products. Its financial flexibility is therefore important not only to its own growth plans but also to its ability to continue investing in manufacturing infrastructure, technologies, technical expertise and services.
Refinancing Strengthens Catalent’s Financial Profile
According to Catalent, the completed transaction is expected to significantly improve its overall financial profile. Lower annual interest costs should help reduce the company’s debt-service burden while providing greater flexibility to allocate capital toward strategic priorities.
Matti Masanovich, Senior Vice President and Chief Financial Officer of Catalent, said the company was highly satisfied with both the outcome of the refinancing and the strong market demand for the transaction. He highlighted the reduction in borrowing costs, improved liquidity and increased financial flexibility as key benefits of the new financing structure.
The new debt arrangements are intended to provide Catalent with a stronger foundation from which to execute its long-term business strategy. By reducing financing expenses, the company expects to have more resources available to invest in areas that can enhance its competitiveness and strengthen its ability to serve customers.
The refinancing also provides Catalent with greater flexibility as it evaluates future opportunities. For a CDMO operating in an industry characterized by ongoing investment in manufacturing capacity, advanced technologies and specialized services, access to sufficient liquidity can be an important factor in maintaining long-term growth.
$600 Million Revolving Credit Facility Expands Liquidity
A central component of the refinancing is Catalent’s new $600 million revolving credit facility. The facility is supported by a syndicate of 10 global institutional banks, broadening the company’s banking relationships and strengthening its access to capital.
Following completion of the refinancing, Catalent has approximately $1.1 billion in available liquidity, including cash on hand and availability under its revolving credit facility. This liquidity position gives the company additional financial resources to manage its operations, address business requirements and pursue strategic investments.
The expanded banking group also provides Catalent with a broader network of financial partners. A diversified banking relationship can offer companies additional flexibility when managing capital requirements and navigating changing financial-market conditions.
For Catalent, the new revolving credit facility complements the seven-year Term Loan B and forms an important part of the company’s updated capital structure. While the term loan provides longer-term financing, the revolving facility can provide additional flexibility for working capital requirements and other corporate purposes, subject to the terms of the financing arrangements.
Supporting Investments in People and Capabilities
Catalent President and Chief Executive Officer Alessandro Maselli described the refinancing as another milestone in the company’s efforts to create a stronger organization for the future.
The improved capital structure is expected to enhance Catalent’s ability to invest in its workforce, manufacturing and technical capabilities, global network and relationships with customers. These investments are particularly important in the CDMO sector, where pharmaceutical and biotechnology companies increasingly rely on external development and manufacturing partners to support complex product development and commercialization programs.
Catalent’s operations require substantial expertise across development, manufacturing, supply and related services. Continued investment can help the company maintain and enhance its capabilities while responding to evolving customer requirements.
Maselli emphasized that the financial improvements resulting from the refinancing will provide Catalent with greater ability to invest in its people, capabilities, network and customer partnerships. The company’s broader objective remains focused on developing, manufacturing and supplying products intended to help people live better and healthier lives.
Importance of Financial Flexibility for the CDMO Industry
The refinancing also highlights the importance of financial flexibility within the contract development and manufacturing industry. Pharmaceutical and biotechnology companies increasingly seek specialized partners capable of supporting products throughout various stages of development and manufacturing. CDMOs must therefore continue investing in facilities, technologies, equipment and skilled personnel to meet evolving industry requirements.
Long-term financing can help support these investments while allowing companies to maintain sufficient liquidity for day-to-day operations. By refinancing its existing debt with a new seven-year Term Loan B and establishing a new revolving credit facility, Catalent has created a financing structure intended to provide both stability and flexibility.
The anticipated annual interest savings of approximately $100 million could also have a meaningful impact on the company’s financial resources. Lower interest expenses can improve cash-flow flexibility and potentially allow a greater portion of available capital to be directed toward operational and strategic initiatives.
Strong Institutional Support for the Transaction
The refinancing was led by JPMorgan and Morgan Stanley, reflecting strong institutional participation in the transaction. The involvement of a syndicate comprising 10 global institutional banks further demonstrates the broad financial support for Catalent’s refinancing plans.
Catalent’s debt received ratings of B1 from Moody’s and B+ from S&P, with both agencies assigning stable outlooks. These ratings provide an external assessment of the company’s credit profile and the stability of its financial position following the refinancing.
The successful completion of the transaction also indicates strong market interest in Catalent’s debt financing. The company noted the strong demand for the transaction as an important aspect of its successful execution.
Positioning Catalent for Future Growth
With the refinancing now completed, Catalent enters the next phase of its strategy with a revised capital structure, lower expected financing costs and approximately $1.1 billion of available liquidity.
The company intends to use its strengthened financial position to support continued growth and investments across its business. Areas of focus include its workforce, capabilities, global network and customer relationships. These investments are expected to help Catalent maintain its role as a development and manufacturing partner for pharmaceutical and biotechnology companies.
The refinancing also provides greater financial flexibility at a time when the healthcare industry continues to evolve rapidly. Demand for advanced manufacturing technologies, specialized development services and reliable pharmaceutical supply chains remains an important consideration for drug developers.
By reducing its annual interest expense and increasing liquidity, Catalent aims to create a more sustainable financial foundation while continuing to focus on its core business. The company’s management views the transaction as an important step toward strengthening the organization and creating additional capacity to pursue long-term opportunities.
Overall, Catalent’s completed refinancing represents a significant financial milestone. The new $4.1 billion seven-year Term Loan B, combined with the $600 million revolving credit facility, replaces the company’s existing Term Loan B while providing improved financing terms and greater liquidity. With approximately $1.1 billion in available liquidity and anticipated annual interest savings of around $100 million, Catalent expects to have increased flexibility to invest in its business and support customers.
The company believes the strengthened capital structure will enable it to continue developing its people, technologies, capabilities and customer partnerships while pursuing sustainable long-term growth. As continues operating across the global pharmaceutical and biotechnology ecosystem, the refinancing is expected to provide an important financial foundation for its future development and its mission of helping customers bring healthcare products to patients around the world.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives.
Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.